Liver Cancer Disparities in American Indian and Alaska Native Persons

Recruiting now · Phase 2

Conditions studied: Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B

In brief

We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.

Key facts

Study ID

NCT05304234

Run by

University of Washington

People needed

200

Starts

2022-04-01

Expected to finish

2026-09-01

Last updated by the study team

2024-06-04

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cirrhosis, any etiology, or chronic HBV infection
• High risk of HCC
• Age 18-75
• Competent to provide informed consent

You may not qualify if…

• Prior diagnosis of HCC
• Current suspicion of HCC
• Prior receipt of any organ transplantation
• Participation in another HCC screening trial
• CTP score >=10
• MELD-Na score >20
• GFR<30
• Poor life expectancy (<5 years)
• Contraindication to MRI
• Inability to complete study visits
• Currently pregnant

Where it is running

• Cherokee Nation Health Service — Tahlequah, Oklahoma, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.